



Attorney Docket No.: P28506

Application No.: 10/550,013

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Rudolf FAHRIG et al.

Group Art Unit: 1623

Appl'n No. : 10/550,013

Examiner: M. Henry

Filed : September 23, 2005

For : USE OF 5-SUBSTITUTED NUCLEOSIDES FOR REINFORCING THE
APOPTOTIC EFFECT OF CYTOSTATIC DRUGS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner, which includes information cited and discussed in an Attachment to the Response to the non-final Office Action dated March 18, 2008 (which Response is being filed concurrently herewith):

Fahrig et al., *RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients*, Anti-Cancer Drugs 2006, 17:1045-1056;

Fahrig et al., *Inhibition of Induced Chemoresistance by Cotreatment with (E)-5-(2-Bromovinyl)-2'-Deoxyuridine (RP101)*, Cancer Research 63, 5745-5753, September 15, 2003.

06/19/2008 JADD01 00000047 10550013

01 FC:1806

180.00 DP

Applicants also bring to the attention of the Examiner the following commonly assigned co-pending application:

U.S. Patent Application 11/853,540, filed September 11, 2007.

In accordance with the procedures of the U.S. Patent and Trademark Office, a copy of the U.S. patent application is not enclosed herewith. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.

This Information Disclosure Statement includes a duly completed Form PTO-1449 listing all of the above-cited documents, and includes copies of the listed documents (except the U.S. Patent application). The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.


Because the period defined in 37 C.F.R. 1.97 (b) has passed, but no final Office Action or Notice of Allowance has issued, Applicants include the fee set forth in 37 C.F.R. 1.17 (p) to assure consideration of this Supplemental Information Disclosure Statement. Moreover, this should be considered express authorization to charge any necessary fee for consideration of this Information Disclosure Statement, or to refund any excess fee, to Deposit Account No. 19-0089.

Attorney Docket No.: P28506

Application No.: 10/550,013

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully submitted,
Rudolf FAHRIG et al.

 / Paul A. Braier
Neil F. Greenblum # 42,357
Reg. No. 28,394

June 18, 2008
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191